227 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Amar
    Amar
  4. Norton
    Norton
  5. Kris
    Kris
  6. Morris
    Morris
  7. Mulhall
    Mulhall
  8. Papanicolaou
    Papanicolaou
  9. Tap
    Tap
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (128)
  2. Solid Tumor Oncology Division (97)
  3. Surgery (34)
  4. Survivorship Research (33)
  5. Genitourinary Oncology Service (27)
  6. Division of Subspecialty Medicine (23)
  7. Population Sciences Research Program (20)
  8. Epidemiology and Biostatistics (18)
  9. Hematologic Malignancies, Division of (18)
  10. Breast Medicine Service (17)
  1. "double blind procedure"
Formats
  1. Journal Article (219)
  2. Conference Paper (3)
  3. Correspondence (3)
  4. Editorial (1)
  5. Review (1)
Groups
  1. Department of Medicine (128)
  2. Solid Tumor Oncology Division (97)
  3. Surgery (34)
  4. Survivorship Research (33)
  5. Genitourinary Oncology Service (27)
  6. Division of Subspecialty Medicine (23)

More Groups

People
  1. Howard Scher (10)
  2. Robert Motzer (10)
  3. David Amar (7)
  4. Jose Baselga (7)
  5. Larry Norton (7)
  6. Genovefa Papanicolaou (6)

More People

Years
  1. 2025 (4)
  2. 2024 (21)
  3. 2023 (13)
  4. 2022 (12)
  5. 2021 (5)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Lancet Oncology (20)
  3. New England Journal of Medicine (17)
  4. Clinical Cancer Research (9)
  5. Lancet (8)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (37)
  2. Elsevier Inc. (28)
  3. American Society of Clinical Oncology (21)
  4. Oxford University Press (19)
  5. Lippincott Williams & Wilkins (17)
  6. Massachusetts Medical Society (17)

More Publishers

Results (227)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intravenous mannitol versus placebo during partial nephrectomy in patients with normal kidney function: A double-blind, clinically-integrated, randomized trial
    Journal Article

    Spaliviero, M.; Power, N. E.; Murray, K. S.; Sjoberg, D. D.; Benfante, N. E.; Bernstein, M. L.; Wren, J.; Russo, P.; Coleman, J. A.
    European Urology (2018)

    Fulltext@MSK | Save
  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Coleman, R. L.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A.; Scambia, G.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
    Journal Article

    Dockery, L. E.; Tew, W. P.; Ding, K.; Moore, K. N.
    Gynecologic Oncology (2017)

    Fulltext@MSK | Save
  • RESILIENCE: Phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer
    Journal Article

    Baselga, J.; Zamagni, C.; Gómez, P.; Bermejo, B.; Nagai, S. E.; Melichar, B.; Chan, A.; Mángel, L.; Bergh, J.; Costa, F.; more...
    Clinical Breast Cancer (2017)

    Fulltext@MSK | Save
  • Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: Rationale and design of the CASSINI trial
    Journal Article

    Khorana, A. A.; Vadhan-Raj, S.; Kuderer, N. M.; Wun, T.; Liebman, H.; Soff, G.; Belani, C.; O'Reilly, E. M.; McBane, R.; Eikelboom, J.; more...
    Thrombosis and Haemostasis (2017)

    Fulltext@MSK | Save
  • An important step forward for biosimilars in cancer treatment
    Journal Article

    Schleicher, S. M.; Seidman, A. D.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Journal Article

    Kim, S. B.; Dent, R.; Im, S. A.; Espié, M.; Blau, S.; Tan, A. R.; Isakoff, S. J.; Oliveira, M.; Saura, C.; Wongchenko, M. J.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Journal Article

    von Minckwitz, G.; Procter, M.; de Azambuja, E.; Zardavas, D.; Benyunes, M.; Viale, G.; Suter, T.; Arahmani, A.; Rouchet, N.; Clark, E.; more...
    New England Journal of Medicine (2017)

    Fulltext@MSK | Save
  • Exploratory decision-tree modeling of data from the randomized REACTT trial of tadalafil versus placebo to predict recovery of erectile function after bilateral nerve-sparing radical prostatectomy
    Journal Article

    Montorsi, F.; Oelke, M.; Henneges, C.; Brock, G.; Salonia, A.; d'Anzeo, G.; Rossi, A.; Mulhall, J. P.; Büttner, H.
    European Urology (2016)

    Fulltext@MSK | Save
  • Extending aromatase-inhibitor adjuvant therapy to 10 years
    Journal Article

    Goss, P. E.; Ingle, J. N.; Pritchard, K. I.; Robert, N. J.; Muss, H.; Gralow, J.; Gelmon, K.; Whelan, T.; Strasser-Weippl, K.; Rubin, S.; more...
    New England Journal of Medicine (2016)

    Fulltext@MSK | Save